GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lionco Pharmaceutical Group Co Ltd (SHSE:603669) » Definitions » Scaled Net Operating Assets

Lionco Pharmaceutical Group Co (SHSE:603669) Scaled Net Operating Assets : 0.54 (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Lionco Pharmaceutical Group Co Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Lionco Pharmaceutical Group Co's operating assets for the quarter that ended in Sep. 2024 was ¥873.2 Mil. Lionco Pharmaceutical Group Co's operating liabilities for the quarter that ended in Sep. 2024 was ¥85.1 Mil. Lionco Pharmaceutical Group Co's Total Assets for the quarter that ended in Jun. 2024 was ¥1,448.1 Mil. Therefore, Lionco Pharmaceutical Group Co's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.54.


Lionco Pharmaceutical Group Co Scaled Net Operating Assets Historical Data

The historical data trend for Lionco Pharmaceutical Group Co's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lionco Pharmaceutical Group Co Scaled Net Operating Assets Chart

Lionco Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.34 0.43 0.31 0.31 0.41

Lionco Pharmaceutical Group Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.42 0.48 0.53 0.54

Competitive Comparison of Lionco Pharmaceutical Group Co's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Lionco Pharmaceutical Group Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lionco Pharmaceutical Group Co's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lionco Pharmaceutical Group Co's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Lionco Pharmaceutical Group Co's Scaled Net Operating Assets falls into.



Lionco Pharmaceutical Group Co Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Lionco Pharmaceutical Group Co's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(890.551-127.906)/1855.481
=0.41

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1624.56 - 734.009
=890.551

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=693.518 - 445.185 - 120.427
=127.906

Lionco Pharmaceutical Group Co's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2024 )
=(Operating Assets (Q: Sep. 2024 )-Operating Liabilities (Q: Sep. 2024 ))/Total Assets (Q: Jun. 2024 )
=(873.163-85.106)/1448.073
=0.54

where

Operating Assets(Q: Sep. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1205.652 - 332.489
=873.163

Operating Liabilities(Q: Sep. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=349.93 - 257.818 - 7.006
=85.106

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lionco Pharmaceutical Group Co Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Lionco Pharmaceutical Group Co's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Lionco Pharmaceutical Group Co Business Description

Traded in Other Exchanges
N/A
Address
68 Zetang Nedong commercial building, 2nd Floor, Shannan Prefecture, CHN
Lionco Pharmaceutical Group Co Ltd is engaged in the research and development of medicines. The product portfolio includes - Alanyl glutamine for injection, fructose for injection, inverted sugar for injection, xylitol for injection, riboflavin sodium phosphate for injection, and water-soluble vitamin for injection.
Executives
Zhang Jun Ke Director
Wang Wen Nan Director
Tao Xiao Gang Director
Tao Ling Gang Director
Tao Ling Ping Director

Lionco Pharmaceutical Group Co Headlines

No Headlines